Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Stem cell jab could replace surgery for painful thumb arthritis

NCT ID NCT05708430

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests the safety of injecting a patient's own stem cells (from fat tissue) into the thumb joint to treat painful thumb arthritis when standard treatments have failed. The goal is to see if this injection can control the disease and avoid the need for surgery. The trial involves 12 adults with moderate thumb arthritis who are already candidates for surgery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 12 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2024

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Rhizarthrosis DELL stage 1 to 3 * Symptomatic medical treatment for a period of at least 6 months (analgesic, orthosis, anti-inflammatory, etc. or intra-articular infiltration of the trapezio-metacarpal joint) which has become ineffective (surgical stage) * EVA pain ≥ 4 * Quick Dash or PRWHE ≥ 20/100 * Affiliation to a social security scheme * Person who has read and understood the information letter and signed the consent form Exclusion Criteria: * History of intra-articular injection of the trapezio-metacarpal (corticoid or hyaluronic acid) in the last 6 months * Body Mass Index \< 18 kg/m2 * Contraindication to general or local anesthetics including XYLOCAINE 10 mg/mL ADRENALINE 0.005 mg/mL, solution for injection * Contraindication to sedation or general anesthesia (left to the discretion of the anesthesiologist) * Contraindication to liposuction (eg bleeding disorder) * Documented severe allergy to conventional antibiotics such as β-lactams, cyclins, macrolides, quinolones, aminoglycosides, etc… * Known hypersensitivity to human albumin or to any of the excipients (VIALEBEX 200 g/L, solution for infusion) * A general or local infection near the sampling or injection sites * Any surgery scheduled over the duration of the study of the hand (carpal tunnel type operation) or upper limb that may have an impact on the assessment of pain and/or functional indices * Persons on immunosuppressants: corticosteroid therapy \> 10 mg/d, methotrexate \> 25 mg/week, mycofenolate mofetil \> 3 grams/d, azathioprine \> 200 mg/d and intravenous cyclophosphamide and any biotherapy in the 90 days preceding the medical visit. inclusion * Congenital or acquired immune deficiency * Prescription of a new systemic treatment that may influence the condition of the hand (vasodilator or immunosuppressant) in the 90 days preceding inclusion * Persons infected with HIV, HCV, HBV, HTLV and syphilis * Contraindication to MRI, (eg, due to presence of pacemakers or other incompatible foreign material or claustrophobia) * Contraindication to the injection of gadolinated contrast product (gadolinium) for performing MRI (history of hypersensitivity to gadolinated contrast products) * Active COVID-19 infection (PCR positive) * Any cardiovascular, metabolic, endocrine, psychiatric or cancerous pathology in uncontrolled evolution

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Rhizarthrosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHU CAEN

    RECRUITING

    Caen, 14033, France

  • Chu Amiens

    RECRUITING

    Amiens, 80054, France

  • Chu Rouen

    RECRUITING

    Rouen, 76031, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.